Year-end Sale % OFF 
Abstract
Aim of the study: Clarification for the time of the clinical improvement after management COVID-19 pneumonia versus normal gradation of common workup is the target for the current study. Background: COVID-19 pneumonia is a current serious international pandemic infection. Generally, in medical diseases, the clinical response is commonly parallel to laboratory and radiological improvement. This rule may be different in COVID-19 pneumonia. Method of study and patients: The author reported retrospective-observational 47-case report series. The study was conducted in a physician outpatient clinic thorough nearly 12-months, starting from Jun 9, 2020, and, ended on May 8, 2021. All included cases were COVID-19 pneumonia and treated with conventional antibiotics, anticoagulants, and steroids. Results: The mean ±SD age was: 50.08 (14.9) years, with male sex predominance (55.32%). The mean days of clinical versus leukocytosis, neutrophilia, and lymphopenia improvement (0.84 ±0.49, 13.05 ±6.44, 13.05 ±7.01, 13.05 ±7.01).The mean ±SD days of clinical versus CRP, D-dimer, s. ferritin, and LDH improvement (0.84 ±0.49, 12.2 ±3.25, 12.2 ±6.21, 12.3 ±5.46, 20.92± 9.48). The mean days of clinical versus radiological and electrocardiographic improvement (0.84 ±0.49, 15.74 ±5.25, 11.45 ±5.45). The test was statistically significant in all the above tests (p-value is < .00001) Conclusions: Yasser’s COVID-19 Discrepancy phenomenon is a novel descriptive phenomenon that is always seen in all COVID-19 pneumonia. Initial dramatic improvement of the clinical status of COVID-19 pneumonic patient, not a simultaneously after the management, not a coincide with laboratory, radiological, and electrocardiographic workup. Further larger studies for the study medical regimen with considering of “Yasser’s COVID-19 Discrepancy phenomenon” is recommended.
Highlights
Yasser’s COVID-19 Discrepancy phenomenon is a novel descriptive phenomenon that is always seen in all COVID-19 pneumonia
The recognition and differentiation between the more severe COVID-19 versus nonsevere patients using the general laboratory tests will be entirely valuable for clinicians in predicting the disease progression [2]
There is a strong need for recognizing the mortality predictors that permit clinicians to rapidly triage severe COVID-19 patients into Intensive care units (ICUs) at hospitalization [3]
Summary
ISSN: 2690-1919 of COVID-19 pandemic, peripherally as part of the diagnostic work-up, but mostly to help define patient prognosis and to guide clinical management [1]. The recognition and differentiation between the more severe COVID-19 versus nonsevere patients using the general laboratory tests will be entirely valuable for clinicians in predicting the disease progression [2]. Laboratory data and chest CT have been used during the COVID-19 pandemic, mainly to determine patient prognosis and guide clinical management [4]. COVID-19 pneumonia is a current serious international pandemic infection. In medical diseases, the clinical response is commonly parallel to laboratory and radiological improvement. This rule may be different in COVID-19 pneumonia
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
